MIFEGYNE Tablet Ref.[8334] Active ingredients: Mifepristone

Source: Medicines & Healthcare Products Regulatory Agency (GB)  Revision Year: 2019  Publisher: Nordic Group B.V., Siriusdreef 22, 2132 WT Hoofddorp, The Netherlands

Therapeutic indications

  • Medical termination of developing intra-uterine pregnancy.
    • In sequential use with a prostaglandin analogue, up to 63 days of amenorrhea (see section 4.2).
  • Softening and dilatation of the cervix uteri prior to surgical termination of pregnancy during the first trimester.
  • Preparation for the action of prostaglandin analogues in the termination of pregnancy for medical reasons (beyond the first trimester).
  • Labour induction in foetal death in utero.
    • In patients where prostaglandin or oxytocin cannot be used.

Posology and method of administration

Posology

Medical termination of developing intra-uterine pregnancy

The method of administration will be as follows:

Up to 49 days of amenorrhea:

Mifepristone is taken as a single 600 mg (i.e. 3 tablets of 200 mg each) oral dose, followed 36 to 48 hours later, by the administration of the prostaglandin analogue: misoprostol 400 μg orally, or gemeprost 1 mg per vaginam.

Between 50-63 days of amenorrhea:

Mifepristone is taken as a single 600 mg (i.e. 3 tablets of 200 mg each) oral dose, followed 36 to 48 hours later, by the administration of the prostaglandin analogue gemeprost 1 mg per vaginam.

Alternatively, 200 mg of mifepristone (i.e. 1 tablet of 200 mg) can also be used in a single oral dose, followed 36 to 48 hours later, by the administration of the prostaglandin analogue gemeprost 1 mg per vaginam (see section 5.1. pharmacodynamic properties).

Information on the posology of misoprostol or gemeprost can be found in the respective product information.

Softening and dilatation of the cervix uteri prior to surgical termination of pregnancy during the first trimester

Mifepristone is taken as a single 200 mg (1 tablet) oral dose, followed 36 to 48 hours later (but not beyond) by surgical termination of pregnancy.

Preparation for the action of prostaglandin analogues in the termination of pregnancy for medical reasons

Mifepristone is taken as a single 600 mg (i.e. 3 tablets of 200 mg each) oral dose, 36 to 48 hours prior to scheduled prostaglandin administration which will be repeated as often as indicated.

Labour induction in foetal death in utero

Mifepristone is taken as a single 600 mg (e.g. 3 tablets of 200 mg each) oral daily dose, for two consecutive days.

Labour should be induced by the usual methods if it has not started within 72 hours following the first administration of mifepristone.

Vomiting within 45 minutes after the intake could lead to a decrease in mifepristone efficacy: oral intake of a new mifepristone 600 mg dose (e.g. 3 tablets of 200 mg each) is recommended in this case.

Paediatric population

Only limited data are available on the use of mifepristone in adolescents.

Method of administration

Mifepristone tablets are for oral use only and should not be taken by any other route of administration.

Overdose

No case of overdose has been reported.

In the event of accidental massive ingestion, signs of adrenal failure might occur. Signs of acute intoxication may require specialist treatment including the administration of dexamethasone.

Shelf life

4 years.

Nature and contents of container

PVC/aluminium perforated unit dose blister packs of 1, 3 × 1, 15 × 1 or 30 × 1 tablets.

Not all pack sizes may be marketed.

Special precautions for disposal and other handling

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.